Jubilant Pharmova Approves FY26 Results, 500% Dividend

Board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Recommended a final dividend of ₹5 per equity share (500%) for FY26, with July 24, 2026 as the record date.
Statutory auditors, Walker Chandiok & Co LLP, issued unmodified opinions on both standalone and consolidated financial results.
Consolidated FY26 net profit stood at ₹3,975 million with basic EPS of ₹25.15.